{"id":352,"date":"2020-07-07T06:02:23","date_gmt":"2020-07-07T06:02:23","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=352"},"modified":"2020-07-07T06:02:23","modified_gmt":"2020-07-07T06:02:23","slug":"06-july-2020-favipiravir-low-mortality-rate-with-combination-treatment-of-favipiravir-and-nafamostat-mesylate","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/06-july-2020-favipiravir-low-mortality-rate-with-combination-treatment-of-favipiravir-and-nafamostat-mesylate\/","title":{"rendered":"(06 July 2020) Favipiravir &#8211; low mortality rate with combination treatment of favipiravir and nafamostat mesylate"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series<\/p>\n<p class=\"\"><a href=\"https:\/\/doi.org\/10.1186\/s13054-020-03078-z\">https:\/\/doi.org\/10.1186\/s13054-020-03078-z<\/a><\/p>\n<p class=\"\">This is the first report on nafamostat mesylate treatment in combination with favipiravir against Covid-19. No interruption of antiviral treatment occurred due to adverse drug reactions except for one patient who developed hyperkalemia on day 9 (by nafamostat mesylate). All 11 patients had at least 33 days of hospital follow-up. As of May 22, 1 patient, who had a do-not-resuscitate order, died on ICU day 7. Seven patients were successfully weaned from MV [median duration of MV 16 days (IQR, 10 to 19 days)] and 9 and 7 patients were discharged from the ICU and the hospital, respectively.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series https:\/\/doi.org\/10.1186\/s13054-020-03078-z This is the first report on nafamostat mesylate treatment in combination with favipiravir against Covid-19. No interruption of antiviral treatment occurred due to&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/06-july-2020-favipiravir-low-mortality-rate-with-combination-treatment-of-favipiravir-and-nafamostat-mesylate\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(06 July 2020) Favipiravir &#8211; low mortality rate with combination treatment of favipiravir and nafamostat mesylate&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11,49],"tags":[26,50],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/352"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=352"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/352\/revisions"}],"predecessor-version":[{"id":353,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/352\/revisions\/353"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}